Can Nurix Therapeutics, Inc. cover its short-term obligations?

Its current ratio is 6.01 — current assets exceed current liabilities.

Where does Nurix Therapeutics, Inc.'s balance sheet data come from?

Every line is extracted from Nurix Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Nurix Therapeutics, Inc. NRIX Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Cash and cash equivalents	$247.93M+124%	$110.9M+99.7%	$55.53M-15.1%	$65.38M-18.8%
Restricted cash	$968K+7.4%	$901K0.0%	$901K0.0%	$901K+215%
Prepaid expenses and other current assets	$50.22M+57.7%	$31.85M-8.2%	$34.71M-12.2%	$39.51M+47.3%
Accrued investment income	$1.5M0.0%	$1.5M—	——	——
Total current assets	$606.82M-2.0%	$619.39M+110%	$295.5M-7.2%	$318.45M+2.4%
Property and equipment, net	$22.49M+26.7%	$17.76M+5.6%	$16.81M-2.1%	$17.16M+51.3%
Accumulated depreciation	$37.78M+9.5%	$34.5M+31.4%	$26.25M+33.4%	$19.67M—
Operating lease right-of-use assets	$50.52M+79.5%	$28.14M-9.6%	$31.14M+152%	$12.35M-11.9%
Deferred tax assets	$9.32M+75.4%	$5.31M—	——	——
Other non-current assets	$7.34M+132%	$3.16M-17.4%	$3.82M-4.9%	$4.02M+42.0%
Available-for-sale securities	$0—	$0—	$0—	——
Total assets	$688.14M+2.8%	$669.34M+88.2%	$355.6M-14.7%	$416.76M-12.6%
Accounts payable	$11.22M-2.3%	$11.48M+79.4%	$6.4M+26.4%	$5.06M-23.8%
Accrued expenses	$21.54M+29.5%	$16.63M+8.7%	$15.3M+16.2%	$13.16M—
Deferred revenue	$17.58M-54.2%	$38.36M-20.2%	$48.1M+27.8%	$37.63M-8.7%
Operating lease liabilities, current	$2.82M-64.8%	$8.01M+7.0%	$7.49M+35.4%	$5.53M+43.7%
Contract liabilities	$10.01M-61.8%	$26.21M-41.8%	$45.02M+25.2%	$35.97M-39.0%
Income taxes payable	$1.06M-14.4%	$1.24M+4,023%	$30K-64.7%	$85K—
Accrued interest	$200K—	——	——	——
Total current liabilities	$86.47M-9.8%	$95.85M+10.2%	$86.96M+23.1%	$70.66M+6.6%
Deferred tax liabilities	$14.43M+137%	$6.09M—	——	——
Operating lease liabilities, non-current	$52.91M+161%	$20.29M-12.3%	$23.13M+259%	$6.43M-30.0%
Total liabilities	$149.39M+4.9%	$142.35M-8.2%	$155.11M+37.2%	$113.06M-15.9%
Preferred stock	$0—	$0—	$0—	$0—
Common stock	500M0.0%	500M+1,020,308%	49K+4.3%	47K+4.4%
Additional paid-in capital	$1.54B+21.8%	$1.27B+69.6%	$746.3M+5.2%	$709.22M+25.8%
Retained earnings	-$1B-35.8%	-$738.77M-35.5%	-$545.2M-35.9%	-$401.25M-81.7%
Accumulated other comprehensive income (loss)	$105K-30.0%	$150K+123%	-$655K+84.8%	-$4.32M-610%
Total stockholders' equity	$538.75M+2.2%	$526.99M+163%	$200.49M-34.0%	$303.7M-11.3%
Total liabilities and stockholders' equity	$688.14M+2.8%	$669.34M+88.2%	$355.6M-14.7%	$416.76M-12.6%
Available-for-Sale Debt Securities	$345.98M-30.7%	$499.59M+114%	$233.28M—	——
Available-for-Sale Debt Securities - Amortized Cost	$587.24M-0.4%	$589.82M—	——	——
Available-for-Sale Debt Securities - Unrealized Loss Position (>=12 Months)	0-100%	4M—	0—	0—
AFS and Trading Securities - Unrealized Loss Position (>=12 Months)	$0-100%	$3.98M—	——	——
AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value	$68.76M-58.6%	$166.16M—	——	——
Available-for-Sale Debt Securities - Unrealized Loss Position (<12 Months)	$68.76M-58.6%	$166.16M—	——	——
Available-for-Sale Debt Securities - Unrealized Loss Position	$10K-93.5%	$153K—	——	——
AFS and Trading Securities - Unrealized Loss Position (>=12 Months) Fair Value	$0-100%	$3.98M—	——	——
AFS and Trading Securities - Unrealized Loss Position Fair Value	$68.76M-59.6%	$170.14M—	——	——
AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value	$68.76M-58.6%	$166.16M—	——	——
Cash, Cash Equivalents, and Marketable Securities	$68.76M-59.6%	$170.14M—	——	——
Cash Cash Equivalents And Short Term Investments	$592.9M—	——	——	——
Debt securities - current	$345.98M-30.7%	$499.59M+114%	$233.28M—	——
Deferred Tax Assets and Other Non-Current Assets	$7.34M+132%	$3.16M-17.4%	$3.82M-4.9%	$4.02M+42.0%
Net Investment in Lease	$50.52M+79.5%	$28.14M-9.6%	$31.14M+152%	$12.35M-11.9%
Operating lease right-of-use assets	$50.52M+79.5%	$28.14M-9.6%	$31.14M+152%	$12.35M-11.9%
Other non-current assets	$7.34M+132%	$3.16M-17.4%	$3.82M-4.9%	$4.02M+42.0%
Property, plant and equipment at cost	$60.27M+15.3%	$52.26M+21.4%	$43.06M+16.9%	$36.83M—
Operating Lease Right-of-Use Assets in Other Assets	$50.52M+79.5%	$28.14M-9.6%	$31.14M+152%	$12.35M-11.9%
Software and Technology Licenses, Net	$7.34M+132%	$3.16M-17.4%	$3.82M-4.9%	$4.02M+42.0%
Tax Credit Carryforward Valuation Allowance	$331.25M+45.9%	$227.05M—	——	——
Accrued Manufacturing Costs	$21.54M+29.5%	$16.63M+8.7%	$15.3M+16.2%	$13.16M—
Accrued Progress Collections and Price Adjustments	$10.01M-61.8%	$26.21M-41.8%	$45.02M+25.2%	$35.97M-39.0%
Accrued expenses and other current liabilities	$54.85M+44.4%	$37.99M+52.2%	$24.97M+11.3%	$22.43M+54.2%
Compensation and benefits	$21.54M+29.5%	$16.63M+8.7%	$15.3M+16.2%	$13.16M—
Other accrued liabilities	$2.1M-7.9%	$2.28M+203%	$751K-50.0%	$1.5M—
Operating Lease Liability Payments - 2024 (Lessee)	$9.18M—	——	——	——
Operating Lease Liability Payments - 2025 (Lessee)	$14.25M—	——	——	——
Lease Liability Payments - Due Year Two	$9.18M—	——	——	——
Lease Liability Payments - Due Year Three	$13.46M—	——	——	——
Lease Liability Payments - Due Year Four	$14.25M—	——	——	——
Lease Liability Payments - Remainder of Fiscal Year	$6.29M—	——	——	——
Operating Lease Liability Payments Due	$82.5M—	——	——	——
Operating Lease Liability - Undiscounted Excess Amount	$18.77M—	——	——	——
Professional Service Fees Payable	$1.94M+20.4%	$1.62M-8.0%	$1.76M+40.4%	$1.25M—
Contract Liabilities, Non-Current	$10.01M-61.8%	$26.21M-41.8%	$45.02M+25.2%	$35.97M-39.0%
Operating Lease Liability Payments - 2026 (Lessee)	$13.46M—	——	——	——
Operating Lease Liability Payments - 2027 (Lessee)	$14.69M—	——	——	——
Operating Lease Liability Payments - 2028 (Lessee)	$14.25M—	——	——	——
Operating Lease Liability Payments - 2029 (Lessee)	$14.69M—	——	——	——
Lease Liability Payments - Due After Year Five	$24.63M—	——	——	——
Operating Lease Liability Payments - Thereafter (Lessee)	$24.63M—	——	——	——
Deferred revenue, net of current portion	$10.01M-61.8%	$26.21M-41.8%	$45.02M+25.2%	$35.97M-39.0%
Total debt	$55.73M+96.9%	$28.3M-7.5%	$30.61M+156%	$11.96M-8.2%
Unrecognized Tax Benefits	$32.31M+47.7%	$21.87M+41.0%	$15.51M+51.1%	$10.26M—
Unrecognized Tax Benefits - Impacting Effective Tax Rate	$500K—	——	——	——
AFS and Trading Securities - Unrealized Loss Position (>=12 Months) Accumulated Loss	$0-100%	$15K—	——	——
Common Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.00—
Common Stock Shares Issued	101.8M+34.2%	75.9M+55.7%	48.7M+3.3%	47.2M—
Convertible Preferred Stock Authorized Shares	10M0.0%	10M0.0%	10M0.0%	10M—
Convertible Preferred Stock Issued Shares	0—	0—	0—	0—
Convertible Preferred Stock Outstanding Shares	0—	0—	0—	0—
Additional paid-in capital	$1.54B+21.8%	$1.27B+69.6%	$746.3M+5.2%	$709.22M+25.8%
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$102K+34.2%	$76K+55.1%	$49K+4.3%	$47K+4.4%
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding	$0—	$0—	$0—	$0—
Investments - Gross Unrealized Losses	$68.76M-59.6%	$170.14M—	——	——
Preferred Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.00—
Share-Based Payment - Unrecognized Cost of Nonvested Awards	$56.1M—	——	——	——
Shares Reserved for Future Issuance Under Stock Plans	26.6M+9.6%	24.3M+29.1%	18.8M+4.5%	18M—
Unrealized Gains on Investments	$115K-62.0%	$303K—	——	——
Unrealized Losses on Investments (Before Tax)	$10K-93.5%	$153K—	——	——
Cumulative Cost Basis	$60.27M+15.3%	$52.26M+21.4%	$43.06M+16.9%	$36.83M—
Accrued And Other Liabilities Current	$54.85M+44.4%	$37.99M—	——	——
Accrued clinical	$13.26M+186%	$4.64M—	——	——
Accrued contract research and lab supplies	$14.95M+28.9%	$11.6M—	——	$6.43M—
Professional service fees	$1.94M+20.4%	$1.62M-8.0%	$1.76M+40.4%	$1.25M—
Area of office space leased	57.9K—	——	——	——
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax	$10K-93.5%	$153K—	——	——
Gross Unrealized Gains	$115K-62.0%	$303K—	——	——
Common stock, capital shares reserved for future issuance	$26.65M+9.6%	$24.31M+29.1%	$18.83M+4.5%	$18.02M—
Common stock, par value (in dollars per share)	$00.0%	$00.0%	$00.0%	$0—
Common stock, shares authorized (in shares)	$500M0.0%	$500M0.0%	$500M0.0%	$500M—
Common stock, shares issued (in shares)	$101.81M+34.2%	$75.87M+55.7%	$48.72M+3.3%	$47.17M—
Common Stock, Shares, Outstanding	$101.81M+34.2%	$75.87M+55.7%	$48.72M+3.3%	$47.17M—
Unrealized gain, short-term	$115K-62.0%	$303K—	——	——
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax, Current	$10K-93.5%	$153K—	——	——
Available-for-sale securities, allowance for credit loss	$0—	$0—	$0—	——
Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss	$587.24M-0.4%	$589.82M—	——	——
Investments	$345.88M-30.7%	$499.44M+114%	$233.28M-4.7%	$244.67M—
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss	$0-100%	$15K—	——	——
Less than 12 months	$68.76M-58.6%	$166.16M—	——	——
12 months or more	$0-100%	$3.98M—	——	——
Number of Securities, Greater than 12 months	$0—	$0—	$0—	$0—
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss	$10K-92.8%	$138K—	——	——
Estimated Fair Value	$587.35M-0.4%	$589.97M—	——	——
Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss	$10K-93.5%	$153K—	——	——
Debt Securities, Available-for-Sale, Unrealized Loss Position	$68.76M-59.6%	$170.14M—	——	——
Deferred Tax Liabilities, Gross	$14.43M+137%	$6.09M—	——	——
Deferred offering costs	$100K0.0%	$100K—	——	——
Accrued expenses and other liabilities	$5.26M+64.5%	$3.2M—	——	——
Capitalized research and experimental expenses	$132.84M+102%	$65.73M—	——	——
Deferred Tax Assets, Gross	$345.68M+48.3%	$233.14M—	——	——
Deferred Tax Assets, Net	$0—	$0—	——	——
Deferred Tax Assets, Net of Valuation Allowance	$14.43M+137%	$6.09M—	——	——
Operating lease liabilities	$15.92M+160%	$6.13M—	——	——
Deferred Tax Assets, Operating Loss Carryforwards	$106.45M+16.0%	$91.79M—	——	——
R&D credit carryforward	$66.58M+37.8%	$48.31M—	——	——
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost	$9.32M+75.4%	$5.31M—	——	——
Deferred Tax Assets, Valuation Allowance	$331.25M+45.9%	$227.05M—	——	——
Valuation allowance offsetting unrecognized tax benefits	$31.8M—	——	——	——
Deferred Tax Liabilities Operating Lease Right Of Use Assets	$14.43M+137%	$6.09M—	——	——
Cost not yet recognized	$56.1M—	——	——	——
Interest receivable on interest rate and cross currency swaps	$1.5M0.0%	$1.5M—	——	——
Lessee Operating Lease Liability Payments Due	$82.5M—	——	——	——
Lessee, Operating Lease, Liability, Tenant Improvement Allowance	$8M—	——	——	——
Lessee Operating Lease Liability Undiscounted Excess Amount	$18.77M—	——	——	——
Operating Lease Weighted Average Discount Rate Percent	$0.07—	——	——	——
Preferred Stock, Par or Stated Value Per Share	$00.0%	$00.0%	$00.0%	$0—
Preferred Stock, Shares Authorized	$10M0.0%	$10M0.0%	$10M0.0%	$10M—
Preferred Stock, Shares Issued	$0—	$0—	$0—	$0—
Preferred Stock, Shares Outstanding	$0—	$0—	$0—	$0—
Unrecognized tax benefits	$32.31M+47.7%	$21.87M+41.0%	$15.51M+51.1%	$10.26M—
Interest accrued	$200K—	——	——	——
Amount that if recognized, would affect the effective tax rate or regulatory liability	$500K—	——	——	——
Working capital	$520.3M—	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Can Nurix Therapeutics, Inc. cover its short-term obligations?: Its current ratio is 6.01 — current assets exceed current liabilities.
Where does Nurix Therapeutics, Inc.'s balance sheet data come from?: Every line is extracted from Nurix Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.